Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial

被引：41

作者：

Azim, Hatem A. ^{[1
,2
]}

Rothe, Francoise ^{[1
]}

Monica Aura, Claudia ^{[3
]}

Bavington, Malcolm ^{[4
]}

Maetens, Marion ^{[1
]}

Rouas, Ghizlaine ^{[1
]}

Gebhart, Geraldine ^{[5
]}

Gamez, Cristina ^{[6
]}

Eidtmann, Holger ^{[7
]}

Baselga, Jose ^{[8
]}

Piccart-Gebhart, Martine ^{[9
]}

Ellis, Catherine ^{[10
]}

Vuylsteke, Peter ^{[11
]}

Cure, Herve ^{[12
]}

Domont, Julien ^{[13
]}

Ferro, Antonella ^{[14
]}

Carlos Toral-Pena, Juan ^{[15
]}

de Azambuja, Evandro ^{[2
,9
]}

Sotiriou, Christos ^{[1
,9
]}

Di Cosimo, Serena ^{[16
]}

Ignatiadis, Michail ^{[1
,9
]}

机构：

[1] Univ Libre Brussels, Inst Jules Bordet, Breast Canc Translat Res Lab, B-1000 Brussels, Belgium

[2] Univ Libre Brussels, Inst Jules Bordet, Dept Med, BrEAST Data Ctr, B-1000 Brussels, Belgium

[3] Vall DHebron Inst Oncol, Lab Mol Pathol, Barcelona, Spain

[4] Frontier Sci Scotland Ltd, Kincraig, Kingussie, Scotland

[5] Univ Libre Brussels, Inst Jules Bordet, Dept Nucl Med, B-1000 Brussels, Belgium

[6] Inst Dianost Imagen ID, PET Unit, Barcelona, Spain

[7] Univ Hosp Kiel, Kiel, Germany

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[9] Univ Libre Brussels, Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium

[10] GlaxoSmithKline, Collegeville, PA USA

[11] St Elizabeth Hosp, Dept Oncol, Namur, Belgium

[12] Inst Jean Godinot, Serv Oncol, Reims, France

[13] Inst Gustave Roussy, Dept Med, Villejuif, France

[14] Santa Chiara Hosp, Dept Med Oncol, Trento, Italy

[15] Hosp Torrevieja, Dept Oncol, Alicante, Spain

[16] Inst Nazl Tumori, Milan, Italy

来源：

BREAST | 2013年 / 22卷 / 06期

关键词：

Circulating tumor cells; pCR; HER2-positive breast cancer; Trastuzumab; Lapatinib; HER2-POSITIVE BREAST-CANCER; RESISTANT PROSTATE-CANCER; OPEN-LABEL; ADJUVANT CHEMOTHERAPY; TRASTUZUMAB; PLUS; HER2; MULTICENTER; SURVIVAL; DISEASE;

D O I：

10.1016/j.breast.2013.08.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: The role of circulating tumor cells (CTCs) in HER2-positive breast cancer patients receiving neoadjuvant therapy is unclear. Patients & methods: We describe the CTC detection rate, HER2 phenotyping and pathological complete response (pCR) in patients enrolled in the NeoALTTO phase III trial. Participation in the CTC sub-study was optional. CTC evaluation was performed centrally using CellSearch (R) at baseline, week 2 and week 18 (prior to surgery) of neoadjuvant therapy. Results: Samples for CTC analysis were available for 51/455 patients randomized. At baseline, week 2 and week 18, we detected >= 1 CTC/22.5 ml in 5/46 (11%), 4/41 (10%), and 5/31 (16%) patients and >= 1 HER2-positive CTC/22.5 ml in 2/46 (4%), 2/41 (5%), and 3/31 (10%) patients with evaluable samples, respectively. 11/51 patients (21%) had >= 1 CTC/22.5 ml in at least one time point. pCR was observed in 3/11 (27.3%) versus 17/40 (42.5%) patients with detectable and no detectable CTCs, respectively (p = 0.36). No pCR was observed in the three patients with detectable HER2-positive CTCs prior to surgery. Conclusion: Numerically lower pCR rates were observed in patients with detectable CTCs, yet the study remains underpowered. A meta-analysis of CTC studies in this setting is warranted. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：1060 / 1065

页数：6

共 36 条

[1]

Circulating Tumor Cells and Circulating Tumor DNA [J].

Alix-Panabieres, Catherine ;

Schwarzenbach, Heidi ;

Pantel, Klaus .

ANNUAL REVIEW OF MEDICINE, VOL 63, 2012, 63 :199-215

[2]

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Swermenhuis, Joost F. ;

Olmos, David ;

Reid, Alison H. M. ;

Vickers, Elaine ;

A'Hern, Roger ;

Levink, Rianne ;

Coumans, Frank ;

Moreira, Joana ;

Riisnaes, Ruth ;

Oommen, Nikhil Babu ;

Hawche, George ;

Jameson, Charles ;

Thompson, Emilda ;

Sipkema, Ronald ;

Carden, Craig P. ;

Parker, Christopher ;

Dearnaley, David ;

Kaye, Stan B. ;

Cooper, Colin S. ;

Molina, Arturo ;

Cox, Michael E. ;

Terstappen, Leon W. M. M. ;

de Bono, Johann S. .

CANCER RESEARCH, 2009, 69 (07) :2912-2918

[3]

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[4]

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[5]

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[6]

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer [J].

Bidard, F. -C. ;

Mathiot, C. ;

Delaloge, S. ;

Brain, E. ;

Giachetti, S. ;

de Cremoux, P. ;

Marty, M. ;

Pierga, J. -Y. .

ANNALS OF ONCOLOGY, 2010, 21 (04) :729-733

[7]

Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].

Cristofanilli, M ;

Budd, GT ;

Ellis, MJ ;

Stopeck, A ;

Matera, J ;

Miller, MC ;

Reuben, JM ;

Doyle, GV ;

Allard, WJ ;

Terstappen, LWMM ;

Hayes, DF .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791

[8]

Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer [J].

De Giorgi, Ugo ;

Valero, Vicente ;

Rohren, Eric ;

Dawood, Shaheenah ;

Ueno, Naoto T. ;

Miller, M. Craig ;

Doyle, Gerald V. ;

Jackson, Summer ;

Andreopoulou, Eleni ;

Handy, Beverly C. ;

Reuben, James M. ;

Fritsche, Herbert A. ;

Macapinlac, Homer A. ;

Hortobagyi, Gabriel N. ;

Cristofanilli, Massimo .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3303-3311

[9]

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial [J].

Fehm, Tanja ;

Mueller, Volkmar ;

Aktas, Bahriye ;

Janni, Wolfgang ;

Schneeweiss, Andreas ;

Stickeler, Elmar ;

Lattrich, Claus ;

Loehberg, Christian R. ;

Solomayer, Erich ;

Rack, Brigitte ;

Riethdorf, Sabine ;

Klein, Christoph ;

Schindlbeck, Christian ;

Brocker, Kerstin ;

Kasimir-Bauer, Sabine ;

Wallwiener, Diethelm ;

Pantel, Klaus .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (02) :403-412

[10]

Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer [J].

Franken, Bas ;

de Groot, Marco R. ;

Mastboom, Walter J. B. ;

Vermes, Istvan ;

van der Palen, Job ;

Tibbe, Arjan G. J. ;

Terstappen, Leon W. M. M. .

BREAST CANCER RESEARCH, 2012, 14 (05)

← 1 2 3 4 →